Table 1 Association of treatment outcome with LCN2 and OSM in axSpA with a single pathway involvement. (A) Left panel: Comparison of treatment outcome in patients with persistent LCN2 elevation (L++) vs transient LCN2 elevation (L+) vs normal LCN2 (Ln). OSM was undetectable in these patients. Right panel: Comparison of treatment outcome in patients with persistent LCN2 elevation (L++) vs transient LCN2 elevation (L+). Pearson’s chi-square test was used to determine significance. (B) Comparison of treatment outcome in patients with persistent OSM positivity (O++) vs transient OSM positivity (O+). CQSQ, clinically quiescent and serologically quiescent; CASA, clinically active and serologically active; CQSA, clinically quiescent and serologically active; CASQ, clinically active and serologically quiescent
